{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:38:28Z","timestamp":1788824308780,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40265-015-0472-0","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T09:03:47Z","timestamp":1442567027000},"page":"1679-1686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["AFREZZA\u00ae (insulin human) Inhalation Powder: A Review in Diabetes Mellitus"],"prefix":"10.1007","volume":"75","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg L.","family":"Plosker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"472_CR1","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report, 2014. 2014. http:\/\/www.cdc.gov . Accessed 14 Aug 2015."},{"issue":"2","key":"472_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","volume":"33","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97\u2013111.","journal-title":"Clin Diabetes."},{"issue":"Suppl. 1","key":"472_CR3","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","volume":"33","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl. 1):S81\u201390.","journal-title":"Diabetes Care."},{"key":"472_CR4","unstructured":"Centers for Disease Control and Prevention. A snapshot: diabetes in the United States. 2014. http:\/\/www.cdc.gov . Accessed 14 Aug 2015."},{"issue":"6","key":"472_CR5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364\u201379.","journal-title":"Diabetes Care."},{"issue":"1","key":"472_CR6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care."},{"issue":"7","key":"472_CR7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1463-1326.2009.01039.x","volume":"11","author":"K Rave","year":"2009","unstructured":"Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11(7):715\u201320.","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"472_CR8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1089\/dia.2011.0037","volume":"13","author":"M Peyrot","year":"2011","unstructured":"Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther. 2011;13(12):1201\u20136.","journal-title":"Diabetes Technol Ther."},{"issue":"11","key":"472_CR9","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2337\/dc08-0315","volume":"31","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Bergenstal R, DeFronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31(11):2177\u201382.","journal-title":"Diabetes Care."},{"key":"472_CR10","unstructured":"US FDA. Afrezza\u00ae (insulin human) inhalation powder: US prescribing information. 2015. http:\/\/www.fda.gov . Accessed 13 Aug 2015."},{"key":"472_CR11","unstructured":"US FDA. FDA briefing information for the April 1, 2014 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. 2014. http:\/\/www.fda.gov . Accessed 14 Aug 2015."},{"key":"472_CR12","unstructured":"Marino MT, Cassidy JP, Smutney CC, et al. Bioequivalence and dose proportionality of Afrezza\u00ae inhalation powder administered using a Gen2 inhaler compared to the MedTone\u00ae inhaler [poster]. In: Diabetes technology meeting; 2010."},{"issue":"9","key":"472_CR13","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s11095-011-0443-4","volume":"28","author":"JP Cassidy","year":"2011","unstructured":"Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere\u00ae insulin inhalation powder administration. Pharm Res. 2011;28(9):2157\u201364.","journal-title":"Pharm Res."},{"issue":"1","key":"472_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2002-19989","volume":"110","author":"S Steiner","year":"2002","unstructured":"Steiner S, Pf\u00fctzner A, Wilson BR, et al. Technosphere\/insulin\u2013proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002;110(1):17\u201321.","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"3","key":"472_CR15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/193229680900300320","volume":"3","author":"R Angelo","year":"2009","unstructured":"Angelo R, Rousseau K, Grant M, et al. Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol. 2009;3(3):545\u201354.","journal-title":"J Diabetes Sci Technol."},{"key":"472_CR16","author":"BW Bode","year":"2015","unstructured":"Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015. doi: 10.2337\/dc15-0075 .","journal-title":"Diabetes Care."},{"key":"472_CR17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-na\u00efve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015. doi: 10.2337\/dc15-0629 .","journal-title":"Diabetes Care."},{"key":"472_CR18","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2015. http:\/\/www.clinicaltrials.gov . Accessed 17 Aug 2015."},{"issue":"9733","key":"472_CR19","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0140-6736(10)60632-0","volume":"375","author":"J Rosenstock","year":"2010","unstructured":"Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244\u201353.","journal-title":"Lancet."},{"issue":"1","key":"472_CR20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/dia.2009.0115","volume":"12","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubin RR. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther. 2010;12(1):49\u201355.","journal-title":"Diabetes Technol Ther."},{"issue":"2","key":"472_CR21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1463-1326.2011.01500.x","volume":"14","author":"P Raskin","year":"2012","unstructured":"Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012;14(2):163\u201373.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"472_CR22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2337\/dc09-1184","volume":"33","author":"AJ Karter","year":"2010","unstructured":"Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733\u20135.","journal-title":"Diabetes Care."},{"issue":"3","key":"472_CR23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.diabres.2014.05.005","volume":"105","author":"WD Strain","year":"2014","unstructured":"Strain WD, Cos X, Hirst M, et al. Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014;105(3):302\u201312.","journal-title":"Diabetes Res Clin Pract."},{"key":"472_CR24","unstructured":"UK Medicines Information. New drugs online: insulin inhaled. 2015. http:\/\/www.ukmi.nhs.uk . Accessed 27 Aug 2015."},{"key":"472_CR25","unstructured":"Mintz ML. Is inhaled insulin a \u2018game changer\u2019? 2014. http:\/\/www.medscape.com . Accessed 14 Aug 2015."},{"issue":"12","key":"472_CR26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nbt1207-1331","volume":"25","author":"GS Mack","year":"2007","unstructured":"Mack GS. Pfizer dumps Exubera. Nature Biotechnol. 2007;25(12):1331\u20132.","journal-title":"Nature Biotechnol."},{"key":"472_CR27","unstructured":"US FDA. Exubera (insulin human [rdna origin]) aerosol powder: US prescribing information. 2008. http:\/\/www.fda.gov . Accessed 14 Aug 2015."},{"issue":"3","key":"472_CR28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/193229680800200325","volume":"2","author":"L Heinemann","year":"2008","unstructured":"Heinemann L. The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008;2(3):518\u201329.","journal-title":"J Diabetes Sci Technol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0472-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0472-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:44Z","timestamp":1559490104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0472-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0472-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}